GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (NAS:VIVS) » Definitions » Cyclically Adjusted PS Ratio

VIVS (VivoSim Labs) Cyclically Adjusted PS Ratio : 0.29 (As of May. 29, 2025)


View and export this data going back to 2011. Start your Free Trial

What is VivoSim Labs Cyclically Adjusted PS Ratio?

As of today (2025-05-29), VivoSim Labs's current share price is $1.88. VivoSim Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $6.57. VivoSim Labs's Cyclically Adjusted PS Ratio for today is 0.29.

The historical rank and industry rank for VivoSim Labs's Cyclically Adjusted PS Ratio or its related term are showing as below:

VIVS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.25   Med: 1.9   Max: 6.59
Current: 0.29

During the past years, VivoSim Labs's highest Cyclically Adjusted PS Ratio was 6.59. The lowest was 0.25. And the median was 1.90.

VIVS's Cyclically Adjusted PS Ratio is ranked better than
94.57% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs VIVS: 0.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

VivoSim Labs's adjusted revenue per share data for the three months ended in Dec. 2024 was $0.016. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.57 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


VivoSim Labs Cyclically Adjusted PS Ratio Historical Data

The historical data trend for VivoSim Labs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VivoSim Labs Cyclically Adjusted PS Ratio Chart

VivoSim Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6.67 4.10 1.86

VivoSim Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.86 1.38 0.92 0.84

Competitive Comparison of VivoSim Labs's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, VivoSim Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Cyclically Adjusted PS Ratio falls into.


;
;

VivoSim Labs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

VivoSim Labs's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.88/6.57
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, VivoSim Labs's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.016/133.1571*133.1571
=0.016

Current CPI (Dec. 2024) = 133.1571.

VivoSim Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.792 99.621 1.059
201506 0.884 100.684 1.169
201509 0.782 100.392 1.037
201512 0.852 99.792 1.137
201603 1.457 100.470 1.931
201606 2.314 101.688 3.030
201609 3.546 101.861 4.635
201612 2.727 101.863 3.565
201703 1.871 102.862 2.422
201706 2.271 103.349 2.926
201709 3.059 104.136 3.912
201712 2.579 104.011 3.302
201803 2.397 105.290 3.031
201806 1.485 106.317 1.860
201809 1.985 106.507 2.482
201812 1.610 105.998 2.023
201903 1.365 107.251 1.695
201906 1.263 108.070 1.556
201909 2.265 108.329 2.784
201912 0.548 108.420 0.673
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 2.069 121.301 2.271
202206 0.000 125.017 0.000
202209 0.106 125.227 0.113
202212 0.180 125.222 0.191
202303 0.223 127.348 0.233
202306 0.103 128.729 0.107
202309 0.000 129.860 0.000
202312 0.007 129.419 0.007
202403 0.035 131.776 0.035
202406 0.032 132.554 0.032
202409 0.020 133.029 0.020
202412 0.016 133.157 0.016

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VivoSim Labs  (NAS:VIVS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


VivoSim Labs Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of VivoSim Labs's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


VivoSim Labs Business Description

Industry
Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075